12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Company News  |  Other News

Teva, Mylan autoimmune, generics news

The Court of Appeal for England and Wales upheld the validity of Teva's U.K. patent 762,888 covering Copaxone glatiramer acetate, maintaining exclusivity for the multiple sclerosis drug in the U.K. until May 2015. Mylan's Generics UK...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >